WO2022075950A1 - Use of calcium (ca) isotopes as drug active substances - Google Patents

Use of calcium (ca) isotopes as drug active substances Download PDF

Info

Publication number
WO2022075950A1
WO2022075950A1 PCT/TR2021/050999 TR2021050999W WO2022075950A1 WO 2022075950 A1 WO2022075950 A1 WO 2022075950A1 TR 2021050999 W TR2021050999 W TR 2021050999W WO 2022075950 A1 WO2022075950 A1 WO 2022075950A1
Authority
WO
WIPO (PCT)
Prior art keywords
calcium
isotopes
cancer
pharmaceutical composition
active substances
Prior art date
Application number
PCT/TR2021/050999
Other languages
French (fr)
Inventor
Burhan GÖBELEZ
Original Assignee
ÖZDURAL, Ahmet Rifat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ÖZDURAL, Ahmet Rifat filed Critical ÖZDURAL, Ahmet Rifat
Publication of WO2022075950A1 publication Critical patent/WO2022075950A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a pharmaceutical composition comprising at least one of the calcium isotopes 42Ca, 43Ca, 44Ca, and 46Ca and the anticancer effect of this pharmaceutical composition.

Description

USE OF CALCIUM (CA) ISOTOPES AS DRUG ACTIVE SUBSTANCES
Technical Field Related to the Invention
The present invention relates to a pharmaceutical composition comprising at least one of the calcium isotopes 42Ca, 43Ca, 44Ca, and 46Ca and the use of this pharmaceutical composition in the treatment of cancer.
State of the Art of the Invention (Prior Art)
The difference between the isotopes of an element is due to the difference in the number of neutrons that the isotopes of this element have. Of these isotopes, non-radioactive ones are called stable isotopes. The calcium element has five major stable isotopes, 40Ca, 42Ca, 43Ca, 44Ca, and 46Ca. 96,94% of calcium in nature consists of 40Ca isotope. New studies indicate that the use of calcium-containing food supplements increases the mortality rate in cancer patients. It is thought that in food support formulations, instead of using naturally occurring calcium containing a very high proportion of 40Ca isotope, using substances enriched in different stable isotopes of calcium as compared to the naturally occurring calcium may prevent the above mentioned problem.
Patent document RU2377007C1 relates to a pharmaceutical composition developed for the treatment of oncological diseases and comprising a calcium chloride compound enriched by the calcium-41 isotope. In this patent on cancer treatment, calcium-41 isotope called cosmogenic nuclide was used. Even though the half-life of the calcium-41 is very long, it is not a stable isotope.
Patent document US 9,261,519 B2 relates to the use of natural isotopes “^Ca/^Ca 87Sr/86Sr as a biomarker that measures changes in bone mineral balance and loss. The two pairs of isotopes can be selected from 48Ca/46Ca, 48Ca/44Ca, 48Ca/43Ca, 48Ca/42Ca, 48Ca/40Ca, 46Ca/44Ca, 46Ca/43Ca, 46Ca/42Ca, 46Ca/40Ca, 44Ca/42Ca, 44Ca/43Ca, 44Ca/40Ca, 43Ca/42Ca, 43Ca/40Ca, and 42Ca/40Ca in the invention. Brief Description and Objectives of the Invention
The present invention relates to a pharmaceutical composition developed for the treatment of cancer comprising water-soluble or insoluble calcium compounds enriched by one or more of the isotopes 42Ca, 43Ca, 44Ca, and 46Ca, different from the isotope ratios of calcium in nature. Calcium isotopes are used as drug active substances against cancer. The advantage of the present invention is that it makes it possible to prepare pharmaceutical compositions for cancer treatment from calcium, which itself has very high LD value, by using the amount corresponding to less than one-thousandth of the LD value of calcium. The pharmaceutical composition comprising the calcium compound comprising one or more of the isotopes 42Ca, 43Ca, 44Ca, and 46Ca may be used in the preparation of the drug to be used in the treatment of cancer.
Detailed Description of the Invention
The invention is a pharmaceutical composition and essentially comprises calcium components at different calcium isotope ratios from those of nature. The pharmaceutical composition to be used in the treatment of cancer includes the calcium compound comprising enriched at least one of the calcium isotopes 42Ca, 43Ca, 44Ca, and 46Ca. The calcium compound is preferably a calcium chloride compound in the invention. The calcium chloride compound comprises at least one of the calcium isotopes 42Ca, 43Ca, 44Ca, and 46Ca, and is contained in the drug to be used in the treatment of cancer.
Cancerous and non-cancerous cell cultures were treated with the solution of calcium compounds enriched by one or more of the isotopes 42Ca, 43Ca, 44Ca, and 46Ca instead of the natural isotope ratio in nature comparatively within the scope of the invention. It has been found as a result that the pharmaceutical mentioned in this invention affects cancer cells much more prominently than cancer- free cells. Calcium isotope ratios in the calcium compounds used in these experiments are different from those in nature and mainly contain isotopes 8% 40Ca, 18% 43Ca, 22% 44Ca, 25% 46Ca, by mass over the total calcium. For example; a solution containing 0.3% calcium chloride by mass was prepared by dissolving the calcium carbonate compound mainly containing isotopes 8% 40Ca, 18% 43Ca, 22% 44Ca, 25% 46Ca, in 0.005 N dilute hydrochloric acid solution. This solution was transferred to the cancer cells in the petri dish and it was found that the cancer cells died within three days. Comparatively, cancer-free cells maintained their normal life span in experiments conducted under the same conditions. .
This invention has shown that naturally stable calcium isotope ratios modified calcium chloride solutions can be used alone or in combination with other elements in the treatment of cancer. Thus, the side effects of conventional chemotherapy and radiation treatments are significantly reduced by the application of solutions prepared from 40Ca, 42Ca, 43Ca, 44Ca, and 46Ca isotopes at different rates.

Claims

1. A pharmaceutical composition to be used in the treatment of cancer, characterized in that it comprises the calcium compound comprising at least one of the calcium isotopes 42Ca, 43Ca, 44Ca and 46Ca.
2. A pharmaceutical composition according to claim 1, characterized in that it comprises the calcium chloride compound comprising at least one of the calcium isotopes 42Ca, 43Ca, 44Ca and 46Ca.
3. A pharmaceutical composition according to claim 2, characterized in that the calcium chloride compound comprises 8% 40Ca, 18% 43Ca, 22% 44Ca, 25% 46Ca and 27% 48Ca calcium isotopes by mass.
4. A drug to be used in the treatment of cancer, characterized in that it comprises the pharmaceutical composition according to any one of the preceding claims.
4
PCT/TR2021/050999 2020-10-07 2021-10-01 Use of calcium (ca) isotopes as drug active substances WO2022075950A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/15950A TR202015950A2 (en) 2020-10-07 2020-10-07 USE OF CALCIUM (CA) ISOTOPES AS ACTIVE DRUG INGREDIENTS
TR2020/15950 2020-10-07

Publications (1)

Publication Number Publication Date
WO2022075950A1 true WO2022075950A1 (en) 2022-04-14

Family

ID=81125902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2021/050999 WO2022075950A1 (en) 2020-10-07 2021-10-01 Use of calcium (ca) isotopes as drug active substances

Country Status (2)

Country Link
TR (1) TR202015950A2 (en)
WO (1) WO2022075950A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060115427A1 (en) * 2004-11-18 2006-06-01 The Regents Of The University Of California Diagnosis and assessment of skeletal related disease using calcium 41
WO2010068130A1 (en) * 2008-12-09 2010-06-17 Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М"" Agent for treating oncological diseases using the isotope calcium-41
WO2012143713A2 (en) * 2011-04-19 2012-10-26 Dspi Ltd Cancer therapy
US20180055879A1 (en) * 2014-12-01 2018-03-01 Peter Y. Novak Pharmaceutical Composition for Improving Health, Cure Abnormalities and Degenerative Disease, Achieve Anti-aging Effect of Therapy and Therapeutic Effect on Mammals and Method Thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060115427A1 (en) * 2004-11-18 2006-06-01 The Regents Of The University Of California Diagnosis and assessment of skeletal related disease using calcium 41
WO2010068130A1 (en) * 2008-12-09 2010-06-17 Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М"" Agent for treating oncological diseases using the isotope calcium-41
WO2012143713A2 (en) * 2011-04-19 2012-10-26 Dspi Ltd Cancer therapy
US20180055879A1 (en) * 2014-12-01 2018-03-01 Peter Y. Novak Pharmaceutical Composition for Improving Health, Cure Abnormalities and Degenerative Disease, Achieve Anti-aging Effect of Therapy and Therapeutic Effect on Mammals and Method Thereof

Also Published As

Publication number Publication date
TR202015950A2 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
Alberts et al. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone
Woloszynska-Read et al. Vitamin D and cancer: clinical aspects
Salazar-Mendiguchía et al. Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist
Gallieni et al. Hyperparathyroidism and anemia in renal failure
Morel et al. Parthenolide selectively sensitizes prostate tumor tissue to radiotherapy while protecting healthy tissues in vivo
Colombini et al. Vitamin B6 metabolism. Utilization of [14C] pyridoxine by the normal mouse
Hercbergs Clinical implications and impact of discovery of the thyroid hormone receptor on integrin αvβ3–a review
WO2022075950A1 (en) Use of calcium (ca) isotopes as drug active substances
HU226984B1 (en) Medical and food products for treating diabetes mellitus and process for producing thereof
Altman et al. The Synergistic Effects of Cortisone and Insulin on Lipogenesis in the Perfused Rat Liver as Studied with [alpha]-C14-acetate
Petrioli et al. Weekly high‐dose calcitriol and docetaxel in patients with metastatic hormone‐refractory prostate cancer previously exposed to docetaxel
US8480995B2 (en) Use of sodium selenosulfate for supplementing selenium and enhancing the therapeutic efficacy of chemotherapy agents, and a rapid process for preparing sodium selenosulfate
AU571846B2 (en) Treating milk fever in cattle
CN104606209A (en) Compound vitamin medicine composition for injection and preparation method of compound vitamin medicine composition
CN112546247A (en) Application of polyhydroxy phenol compound, radiopharmaceutical composition and preparation method
Knypl Growth retardants in relation to the germination of seeds. III. The synergistic, inhibitory effect of (2-chloroethyl) trimethylammonium chloride and coumarin on germination of kale seeds, and its reversal by kinetin and gibberellic acid
KR101605429B1 (en) An injectable cholecalciferol formulation in which production of impurities is suppressed, and a method for preparation thereof
Nassar et al. Synthesis of a 188 Re–DTPMP complex using carrier-free 188 Re and study of its stability
CN109316454B (en) Calcitriol preparation
JP6527736B2 (en) Radiopharmaceutical composition
US6004532A (en) Formulation for Tin-117m /diethylenetriaminepentaacetic acids
CN113766952B (en) Method for producing radiopharmaceutical and radiopharmaceutical
Haddad Jr et al. Phosphorus deprivation: the metabolism of vitamin D3 and 25-hydroxycholecalciferol in rats
EP3639818B1 (en) Glucose consumption promoter and glycolysis promoter
Glazko et al. IS THE PHYSIOLOGICAL ACTIVITY OF POTASSIUM DUE TO ITS NATURAL RADIOACTIVITY?

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21878136

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21878136

Country of ref document: EP

Kind code of ref document: A1